Guardant Health, Inc. GH
We take great care to ensure that the data presented and summarized in this overview for Guardant Health, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GH
View all-
Vanguard Group Inc Valley Forge, PA11.7MShares$371 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11.2MShares$356 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA10.1MShares$321 Million0.04% of portfolio
-
Cadian Capital Management, LP New York, NY6.93MShares$219 Million8.13% of portfolio
-
Deep Track Capital, LP Greenwich, CT6MShares$190 Million5.07% of portfolio
-
Baillie Gifford & CO5.87MShares$186 Million0.1% of portfolio
-
Capital International Investors Los Angeles, CA4.47MShares$142 Million0.02% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.84MShares$122 Million1.55% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL3.34MShares$106 Million0.02% of portfolio
-
Braidwell LP Stamford, CT3.34MShares$106 Million2.17% of portfolio
Latest Institutional Activity in GH
Top Purchases
Top Sells
About GH
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
Insider Transactions at GH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 18
2024
|
Musa Tariq Director |
SELL
Open market or private sale
|
Direct |
116
-3.96%
|
$3,944
$34.85 P/Share
|
|
Dec 15
2024
|
Kumud Kalia Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
323
-1.72%
|
$10,982
$34.76 P/Share
|
|
Dec 15
2024
|
Kumud Kalia Chief Information Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
637
+3.29%
|
-
|
|
Dec 15
2024
|
Myrtle S Potter Director |
BUY
Exercise of conversion of derivative security
|
Direct |
69
+0.5%
|
-
|
|
Dec 15
2024
|
John G. Saia Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
535
-1.57%
|
$18,190
$34.76 P/Share
|
|
Dec 15
2024
|
John G. Saia Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,020
+2.9%
|
-
|
|
Dec 15
2024
|
Craig Eagle Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
711
-2.88%
|
$24,174
$34.76 P/Share
|
|
Dec 15
2024
|
Craig Eagle Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,402
+5.38%
|
-
|
|
Dec 15
2024
|
Chris Freeman Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
597
-1.82%
|
$20,298
$34.76 P/Share
|
|
Dec 15
2024
|
Chris Freeman Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,402
+4.09%
|
-
|
|
Dec 15
2024
|
Musa Tariq Director |
BUY
Exercise of conversion of derivative security
|
Direct |
250
+7.87%
|
-
|
|
Dec 15
2024
|
Michael Brian Bell Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,659
-6.07%
|
$56,406
$34.76 P/Share
|
|
Dec 15
2024
|
Michael Brian Bell Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,272
+5.79%
|
-
|
|
Dec 13
2024
|
Musa Tariq Director |
SELL
Open market or private sale
|
Direct |
2,320
-46.44%
|
$81,200
$35.0 P/Share
|
|
Dec 04
2024
|
Meghan V. Joyce Director |
BUY
Exercise of conversion of derivative security
|
Direct |
67
+0.87%
|
-
|
|
Dec 02
2024
|
Meghan V. Joyce Director |
SELL
Open market or private sale
|
Direct |
100
-1.31%
|
$3,500
$35.9 P/Share
|
|
Dec 01
2024
|
Kumud Kalia Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
360
-1.95%
|
$12,600
$35.61 P/Share
|
|
Dec 01
2024
|
Kumud Kalia Chief Information Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
710
+3.7%
|
-
|
|
Dec 01
2024
|
John G. Saia Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
138
-0.42%
|
$4,830
$35.61 P/Share
|
|
Dec 01
2024
|
John G. Saia Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
263
+0.79%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 769K shares |
|---|---|
| Other acquisition or disposition | 8.44K shares |
| Open market or private purchase | 2.19K shares |
| Payment of exercise price or tax liability | 106K shares |
|---|---|
| Other acquisition or disposition | 8.44K shares |
| Open market or private sale | 21K shares |